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Abstract
Background: The Ras Association Domain Family Member 1 (RASSF1) is one of the most frequently reported
methylation-inactivated tumor suppressor genes in primary pancreatic ductal adenocarcinomas (PDAC). Limited
information is still available about the impact of RASSF1 gene silencing on the expression of its different isoforms in
neoplastic cells.
Methods: A series of 96 primary PDAC, with known clinico-pathological parameters, was tested for RASSF1
methylation status by methylation-specific PCR, RASSF1 locus copy number alterations by fluorescence in situ
hybridization, and Rassf1a protein expression by immunohistochemistry. A further series of 14 xenografted primary
PDAC and 8 PDAC-derived cell lines were tested to obtain a detailed methylation mapping of CpG islands A and C
of the RASSF1 locus by pyrosequencing and to evaluate the expression of Rassf1 variants by qRT-PCR.
Results: Methylation of CpG island A of the RASSF1 gene was observed in 35 % of the tumors and allelic loss of
RASSF1 locus was seen in 30 disomic and in 20 polysomic cases (52 %). Rassf1a immunohistochemical expression
was downregulated in half of primary PDAC, and this downregulation was neither correlated with methylation of
RASSF1 promoter nor with RASSF1 copy number alterations. RASSF1 status did not influence patients’ prognosis. The
expression of the seven RASSF1 isoforms in xenografts and cell lines showed that RASSF1A, RASSF1B, and RASSF1C
isoforms were present in all xenografts and cell lines, whereas RASSF1D, RASSF1E, and RASSF1F isoforms were
variably expressed among samples. RASSF1G was never expressed in either xenografts or cell lines. The variable
expression of RASSF1 isoforms in PDAC xenografts and cell lines was not dependent on RASSF1 methylation status
of CpG islands A and C.
Conclusions: RASSF1 alterations occurring in PDAC mainly consist in variations of expression of the different
isoforms. Different genetic mechanisms seem to contribute to RASSF1 deregulation in this setting, but RASSF1
methylation does not seem to substantially affect RASSF1 isoforms expression.
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Background
A recent genome-wide profiling of DNA methylation of
167 pancreatic ductal adenocarcinomas (PDAC) identified
3522 genes that showed an altered methylation status [1].
Among these genes, the Ras Association Domain Family
Protein 1 (RASSF1) locus showed frequent hypermethyla-
tion, confirming a previous report of RASSF1 locus hyper-
methylation in two thirds of primary PDAC and seven of
eight PDAC cell lines [2].
RASSF1 is a putative tumor suppressor gene that controls
tumor growth by inhibiting the RAS pathway [3–6]. Recent
studies assigned additional complex roles to RASSF1 in cell
life such as promotion of apoptotic signaling, microtubule
stabilization and mitotic progression [7–12]. As constituent
of RAS/PI3K/AKT, RAS/RAF/MEK/ERK and Hippo cancer
pathways, an important role in solid tumors has been sug-
gested [12–14] and, in this context, RASSF1 is one of the
most frequently reported methylation-inactivated tumor
suppressor genes [12, 15]. It has also been reported a prog-
nostic role for RASSF1 methylation in a series of cancer
types (liver, gastric, prostate, bladder, kidney, brain and pi-
tuitary neoplasms), where an altered methylation status has
been associated to a more aggressive biological behaviour
[13, 16–21]. RASSF1 methylation has been also reported as
a good predictor of response to gemcitabine-chemotherapy
in lung cancer [22]. RASSF1 locus on chromosome 3p21.3
generates seven transcript isoforms (RASSF1 A-G) by dif-
ferential promoter usage and alternative splicing [23]. Two
CpG islands are associated to RASSF1: 1) CpG island A,
common to RASSF1A, D, E, F and G, in the promoter re-
gion, and 2) CpG island C in the regulatory region of
RASSF1B and C. RASSF1A and RASSF1C are the major
isoforms and they are ubiquitously expressed in normal tis-
sues [23]. Expression of RASSF1 isoforms has never been
studied in primary PDAC, whereas in PDAC cell lines
RASSF1A was found to be expressed only in cells resulting
unmethylated with a qualitative methylation specific PCR
[2]. Among the remaining RASSF1 variants, only RASSF1F
was tested and found frequently expressed in PDAC cell
lines [2].
PDAC is characterized by a large number of chromo-
somal alterations among which loss of heterozygosity
(LOH) at chromosomal arm 3p21.3, where RASSF1 re-
sides, has been reported to occur as ranging from 43 to
75 % of cases [24–26].
In this study, we report the evaluation of 96 pri-
mary PDAC for Rassf1a protein immunohistochemical
expression, RASSF1 gene copy number by FISH, and
methylation of RASSF1 locus by methylation-specific
PCR. To get insight into the correlation of expression
data and methylation of RASSF1, we used 14 primary
PDACs xenotransplanted in nude mice and 8 PDAC
cell lines to perform a detailed analysis of methylation
of CpG islands A and C of the RASSF1 locus by
DNA pyrosequencing and mRNA expression analysis
of RASSF1 variants by quantitative RT-PCR.
Methods
PDAC tissues
A series of 96 formalin-fixed and paraffin-embedded
(FFPE) primary PDAC, whose clinico-pathological char-
acteristics are shown in Table 1, was considered. The
series was studied for Rassf1a expression by immunohis-
tochemistry (IHC) and RASSF1 gene copy number by
fluorescence in situ hybridization (FISH) by using 4 tis-
sue microarrays (TMAs). The Manual Tissue Arrayer
MTA-1 (Beecher Instruments, Silver Spring, MD) was
used in the assembling of the TMAs and three 1 mm tis-
sue cores per case were included. Ten additional normal
pancreatic parenchyma cores were used as controls and
integrated in the TMAs.
PDAC xenografts and cell lines
Fourteen fresh primary PDAC xenografted in nu/nu
mice (mean age 57 ± 7; Male/Female = 7/7; T3N0M0 = 6,
T3N1M0 = 8; G2 = 10, G3 = 4) [27] and 8 PDAC-derived
cell lines (PACA3, PACA44, PT45, CFPAC, PC, HPAF,
PSN, PANC1) [28] were studied for DNA methylation at
RASSF1 locus and mRNA expression of RASSF1 iso-
forms. Frozen material from neither primary tumors nor
their normal counterparts for these xenografted cancers
was available. Cell lines were grown in RPMI 1640 sup-
plemented with 2 mM glutamine and 10 % FBS and in-
cubated at standard conditions (37 °C, 5 % CO2).
Ethics
The materials used have been collected under Program
853 protocol 298CE 15/02/2002 and Program 1885
protocol 52438 on 23/11/2010. The protocols include in-
formed consent of the patient and were approved by the
local ethics committee of the Integrated University Hos-
pital Trust of Verona. The first approval (prog. 853)
regarded the collection of pancreas samples for use in
molecular research studies. This was later updated (prog.
1885) for the creation of a coordinated biobank for the
collection of samples from all cancer patients that in-
cluded neoplastic and associated local and distant nor-
mal tissue. The approved programs include tissue
processing and storage methods of FFPE tissues of both
neoplastic and normal tissue, including the creation of
tissue microarrays. The latter program included amend-
ments to address the later regulatory issues of data dis-
closure in genomic studies. Animal housing and all the
protocols involving the use of experimental animals in
this study were carried out with the authorization of the
Italian Ministry of Health (approved protocol N. 184/
2008-B).
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Immunohistochemistry (IHC)
Immunostaining was performed on 4 μm-thick FFPE
sections using anti-Rassf1 antibody (HPA040735; Atlas
antibodies, Stockholm, Sweden;1:200 dilution) with an
automatic stainer (Bond instrument, Vision Biosystem
Leica, Milan, Italy) as described previously [29, 30]. Ap-
propriate positive and negative controls were run con-
currently. Rassf1 immunostaining was considered
positive when cells showed unambiguous cytoplasm
staining. Sparse normal exocrine cells showed nuclear
staining, which was not retained for scoring. The inten-
sity of cytoplasmic staining was scored in a four-tiered
scale: 0 = negative, 1 + = weak staining, 2 + = moderate
staining, 3 + = strong staining, similarly to other immu-
nohistochemical study [31].
Fluorescence in situ hybridization (FISH)
FISH assay for RASSF1 locus was performed on four 4-μm-
thick sections from TMAs, using a home-made Spectrum
Orange labeled DNA probe for the relevant region and a
commercially available conjugated Cy3, Spectrum Green
labeled, centromeric enumeration probe (CEP3) (Abbott-
Vysis, Downer Grove, IL, USA). Briefly, BAC clone specific
for chromosome 3p (RP11-894C9), mapping at 3p21.31
and belonging to the Roswell Park Cancer Institute libraries
(Peter J. de Jong at http://bacpac.chori.org/) was selected.
Paraffin sections were hybridized with the probe labeled by
nick translation [32], using 500 ng of probe labeled with
Fluorolink Cy3-dUTP or Fluor-X-dCTP (Amersham,
Buckinghamshire, UK). For each sample, at least 110
nuclei were counted for RASSF1 signals and alpha-
satellite sequences of chromosome 3 centromere
(CEP3), as previously reported [33]. Results were
expressed as the mean value of RASSF1 copy number:
CEP3 signal ratio per cell.
Nucleic acids extraction
Nucleic acids were prepared from FFPE primary PDAC
tissues, and from frozen sections of PDAC xenografts.
Tumor cellularity was manually enriched by microdis-
section to at least 70 %. DNA was purified by QiAamp
DNA Mini Kit (Qiagen), following manufacturer’s in-
structions. RNA was extracted from PDAC cell lines and
xenografts with TRIzol Reagent (Invitrogen) following
manufacturer’s instructions, then treated with DNAse I
(Invitrogen) for 15 min at room temperature, and finally
incubated at 65 °C for 10 min for enzyme inactivation.
Bisulfite treatment of DNA
DNA was chemically modified with sodium bisulfite
using MethylSeq Kit (Applied Biosystems) to convert
unmethylated cytosine to uracil, while methylated cyto-
sines resist to conversion. DNA was incubated with so-
dium bisulfite for 16 h at 50 °C in a heat-block and used
for subsequent experimental procedures.
RASSF1A methylation-specific PCR (MSP)
Methylation-specific PCR (MSP) was performed accord-
ing to Pizzi et al. [34]. Reference unmethylated DNA
was from healthy donor peripheral blood mononuclear
cells. Reference full methylated DNA was CpGenome
Universal Methylated DNA (Chemicon International).
Table 1 Distribution of 96 pancreatic ductal adenocarcinomas grouped by RASSF1/CEP3 status and clinico-pathological features
Parameter Class RASSF1 retained RASSF1 loss RASSF1 loss RASSF1 gain
CEP3 diploid CEP3 diploid CEP3 polyploid CEP3 polyploid
Sex F 14 (56.0 %) 11 (36.7 %) 8 (40.0 %) 6 (28.6 %)
M 11 (44.0 %) 19 (63.3 %) 12 (60.0 %) 15 (71.4 %)
Age Mean 63 58 64 63
pT T3 25 (100.0 %) 28 (93.3 %) 17 (85.0 %) 20 (95.2 %)
T4 0 (0.0 %) 2 (6.7 %) 3 (15.0 %) 1 (4.8 %)
pN N0 5 (20.0 %) 7 (23.3 %) 4 (20.0 %) 3 (14.3 %)
N1 20 (80.0 %) 23 (76.7 %) 16 (80.0 %) 18 (85.7 %)
pM M0 24 (96.0 %) 29 (96.7 %) 18 (90.0 %) 18 (85.7 %)
M1 1 (4.0 %) 1 (3.3 %) 2 (10.0 %) 3 (14.3 %)
Grading G1 0 1 (3.3 %) 0 0
G2 14 (56.0 %) 17 (56.7 %) 11 (55.0 %) 12 (57.1 %)
G3 11 (40.0 %) 12 (40.0 %) 9 (45.0 %) 9 (42.9 %)
TNM II 5 (20.0 %) 7 (23.3 %) 3 (15.0 %) 3 (14.3 %)
III 19 (76.0 %) 20 (66.6 %) 12 (60.0 %) 15 (71.4 %)
IV 1 (4.0 %) 3 (10.0 %) 5 (25.0 %) 3 (14.3 %)
TOTAL - 25 30 20 21
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Methylation-specific DNA pyrosequencing analysis
Bisulfite-modified DNAs were evaluated by pyrose-
quencing [35], using primers and conditions previously
described [36]. DNA pyrosequencing provides the
methylation status of single CpGs at the specific gen-
omic region analyzed. The degree of methylation at each
CpG position was determined from the ratio of C and T
by the Pyro Q-CpG Software (Biotage AB). Pyrosequenc-
ing was performed on the sense and antisense strand of
RASSF1A (nucleotides −163 to +262 in chromosome 3:
50353109–50353534, NC_0000003.10) and of RASSF1C
(nucleotides −86 to +193 in chromosome 3: 50349706–
50349985, NC_0000003.10).
Identification of alternatively spliced mRNA isoforms of
RASSF1 transcribed from CpG island A
RASSF1A is the main transcript isoform arising from
the promoter containing CpG island A and the D, E, F
and G isoforms originate from alternative splicing of
RASSF1A. Taking advantage of their different length,
isoforms A, D, E, F were identified by microfluidic chip-
electrophoretic separation (DNA 1000 chip, 2100 Bioa-
nalyzer, Agilent technologies) of PCR products. PCR
amplification of cDNAs used primers designed in first
and last exon of the gene (NCBI Reference Sequence
NM_007182) and was performed as previously described
[36]. As RASSF1G lacks the last exon of RASSF1, it was
amplified separately with appropriate primers [36].
Quantitative reverse transcription-polymerase chain reaction
(qRT-PCR)
Messenger RNA expression of the major RASSF1 vari-
ants RASSF1A, RASSF1B and RASSF1C was determined
in 14 xenografted PDAC and 8 PDAC cell lines. RNA
samples were retrotranscribed to cDNA using the First
Strand cDNA Synthesis Kit (Roche). A reverse tran-
scriptase minus cDNA was prepared for each sample as
a control. QRT-PCR was carried out as previously de-
scribed [36] in 25 μl total volume containing 4 ng of
cDNA, 1x Power SYBR Green I Master Mix (Applied
Biosystems), 400 nM of each primer. After a starting
denaturation for 10 min at 95 °C, 45 PCR cycles (15 s
95 °C and 1 min 60 °C) have been performed on ABI
PRISM 7900HT SDS instrument (Applied Biosystems).
The relative expression level was calculated using
transcript level of RPLPO as reference gene and the
standard (=1) was the average of the levels of expression
of all samples. QRT-PCR data analysis was performed
according to the comparative method following the User
Bulletin #2 (Applied Biosystems).
DNA sanger sequencing
KRAS (exons 2, 3, and 4) and BRAF (exon 15) genes
mutational status was assessed by Sanger sequencing, as
described elsewhere [37]. PCR products were purified
using Agencourt AMPure XP magnetic beads (Beckman
Coulter) and labelled with BigDye® Terminator v3.1 (Ap-
plied Biosystems). Agencourt CleanSEQ magnetic beads
(Beckman Coulter) were used for post-labeling DNA frag-
ment purification, and sequence analysis was performed
on the Applied Biosystems 3130xl Genetic Analyzer.
Statistical analysis
Pearson’s correlation (r) and Student’s t-test were used
to compare mRNA expression and differentially methyl-
ated regions between groups of samples. Fisher’s exact
test and Cox multivariate model were used to calculate
correlations between results and clinico-pathological
features. p-values less than 0.05 were considered statisti-
cally significant. Where applicable, the tests were two-
tailed. For all the calculations, the R statistical software
package was used (http://www.r-project.org).
Results and discussion
Rassf1a immunohistochemical expression is downregulated
in half of primary PDAC
Rassf1a expression was evaluated by IHC in 10 normal
pancreas, 96 primary PDAC tissues, 14 PDAC xenografts
and 8 PDAC cell line. Normal pancreas had clear
Rassf1a 2+ or 3+ immunoreactivity (Fig. 1) that was uni-
form in acinar cells and insulae, although the latter
showed some degree of heterogeneity from 2+ to 3+.
Some cells at the periphery of the insulae, possibly cor-
responding to non-ß insular cells, were more strongly
stained. PDAC tissues showed a uniform immunostain-
ing among the three different cores of TMAs representa-
tive of each single PDAC. In summary, primary PDAC
showed a variable expression from 0 to 3+ (Fig. 1),
where 7 (7.3 %) cases were negative, 41 (42.7 %) were 1+,
35 (36.5 %) were 2+, and 13 (13.5 %) were 3+ (Additional
file 1: Table S1). On the whole, 50 % of primary PDAC
(48/96) showed a down-regulation (0/1+) of Rassf1a in
comparison to normal pancreas (p = 0.0018, Fisher’s exact
test). Rassf1a expression was not associated to any specific
clinico-pathological parameter.
Rassf1a immunohistochemical expression is downregulated
in half of xenografted PDAC and PDAC cell lines
In xenografted PDAC, Rassf1a expression was 0 in 3
(21 %) cases, 1+ in 5 (36 %) cases and 2+ in 6 (43 %)
cases (Additional file 1: Table S2). Rassf1a was thus
down-regulated (0/1+) in 8 of 14 (57 %) xenografts. All
PDAC cell lines expressed Rassf1a: 4 (50 %) had 1+, 3
(37.5 %) had 2+ and 1 (12.5 %) had 3+ (Additional file 1:
Table S3). Rassf1a was thus down-regulated in 4 of 8
(50 %) PDAC cell lines.
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RASSF1 locus shows frequent copy number alterations in
PDAC
According to CEP3 FISH data, chromosome 3 was in a
disomic status in 55 PDAC and polysomic in 41 (from 3
to 7 signals, mean 3.7). RASSF1 locus was retained in 46
cases and lost in 50 cases (Fig. 2). Thus, the combination
of chromosome 3 ploidy status as assessed by CEP3 and
RASSF1 gene copy number generated four distinct
classes: 1) RASSF1 retained/CEP3 diploid (25 cases), 2)
RASSF1 loss/CEP3 diploid (30 cases), 3) RASSF1 loss/
CEP3 polyploid (20 cases), and 4) RASSF1 retained/
CEP3 polyploid (21 cases) (Table 1 and Additional file 1:
Table S1). Cases distributed uniformly among the four
classes; no significant association was observed consider-
ing RASSF1 status and clinico pathological parameters.
The presence of polysomy in CEP3, independently of the
RASSF1 status, was significantly associated to a worse
prognosis (Additional file 2: Figure S1). Patients with
both disomic CEP3 and RASSF1 had a similar prognosis
compared to patients with disomic CEP3 and loss of
RASSF1.
CpG island A of RASSF1A is frequently methylated in PDAC
Methylation-specific PCR (MSP) detected methylation of
RASSF1A in 34 of 96 (35.4 %) PDAC (Additional file 1:
Table S1). In particular, methylation was detected in 18
of 50 (36 %) PDAC with loss of RASSF1 and in 16 of 46
(34.7 %) PDAC without loss. There was no correlation
between methylation of CpG island A as assessed by
MSP and IHC expression of Rassf1a.
DNA pyrosequencing was used to assess the methyla-
tion level of 51 CpGs within CpG island A of RASSF1A
(17 in the promoter and 34 in the first exon) in 14 xeno-
grafted primary PDAC and 8 PDAC cell lines. Methyla-
tion was detected in 21 % (3/14) of PDAC xenografts
(cases PDX1, PDX4 and PDX5) (Fig. 3 and Additional
file 1: Table S2) and in 62 % (5/8) of PDAC cell lines
(PACA44, PT45, PSN, PANC and PACA3) (Fig. 3 and
Additional file 1: Table S3). The average methylation of
51 CpGs was above 70 % in two xenografts (PDX1 and
PDX4) and 40 % in one (PDX5). Among the five PDAC
cell lines with methylation, two showed an average level
higher than 80 % (PACA44, PT45), two between 50 and
A B C
Fig. 1 IHC Rassf1a expression in normal pancreas and PDAC. a Exocrine and islet cells consistently showed a moderate/strong (2+/3+) Rassf1a
cytoplasmic immunoreaction. b PDAC with only few positive cells, and with a weak reactivity (1+); between neoplastic cells there is a nonspecific
staining deposition. c One of the PDAC cases totally negative (0). Original magnifications 10x and 20x
BA C
Fig. 2 Representative FISH digitalized images of the RASSF1 and chromosome 3 status in PDAC. The DNA probes used were a home-made Spectrum
Orange for the locus specific RASSF1 gene and a commercially available Spectrum Green enumeration CEP3 probe: a diploid status for chromosome 3
and RASSF1 loci; b gains of chromosome 3 (four signals) and two RASSF1 signals reflecting loss in a chromosome 3 tetraploid nucleus; c loss of RASSF1
locus in two diploid chromosome 3 nuclei. The digitalized images are obtained by the High Technology Scan D-Sight/Fluo software (Visia Imaging,
San Giovanni Valdarno, Italy), which also recognizes and circles individual neoplastic DAPI stained nuclei
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70 % (PSN, PANC) and one (PACA3) an average level
below 30 %, due to partial methylation of CpGs from
CpG14 to CpG34 within the first exon. The methylation
status of CpG island A was distributed with no apparent
preferential pattern.
None of the 37 CpG of CpG island C (9 in the pro-
moter and 28 in the first exon) investigated by DNA py-
rosequencing was methylated in either the 14 PDAC
xenografts or the 8 cell lines (Fig. 3).
The variable expression of RASSF1 isoforms in PDAC
xenografts and cell lines is not dependent from CpG islands
methylation
The expression levels of the RASSF1 isoforms were evalu-
ated by real-time qRT-PCR in 14 PDAC xenografts and 8
PDAC cell lines. The three main gene transcripts of the
RASSF1 locus (i.e. RASSF1A, RASSF1B and RASSF1C)
were expressed in all xenografts and cell lines (Additional
file 2: Figures S2 and S3). RASSF1A and RASSF1B expres-
sion levels were correlated (p = 0.010, r = 0.8) in both
xenografts and cell lines.
Among the remaining 4 mRNA isoforms that are gen-
erated from alternative splicing of RASSF1A (RASSF1D,
RASSF1E, RASSF1F, RASSF1G), expression of RASSF1F
was observed in 8/14 (57 %) PDAC xenografts (PDX1,
PDX2, PDX5, PDX6, PDX7, PDX10, PDX12, PDX14)
and in 5/8 (62 %) cell lines (PACA3, CFPAC, PC, HPAF,
PANC), while isoforms D-E were expressed in 2/14
(14 %) xenografts (PDX7 and PDX14) and in 2/8 (25 %)
cell lines (PACA3 and PT45). RASSF1G was never
expressed in either xenografts or cell lines.
No correlation between the expression level of the
RASSF1 isoforms and methylation of CpG islands was
found.
RASSF1 deregulation is not associated to a specific KRAS
mutational profile
Of the 96 presented cases, 92 (96 %) showed mutations
in KRAS gene and none in BRAF gene at Sanger sequen-
cing. Of these 92, we have found: 42 (45.7 %) p.G12D,
31 (33.7 %) p.G12V, 18 (19.5 %) p.G12R, 1 (1.1 %)
p.Q61H. There was not a statistical significance between
any particular mutation and epigenetic, cytogenetic or
clinical parameters. We searched BRAF mutations as it
has been reported that mutations in this gene may be
found in KRAS wild-type cancers and rarely may also be
associated with KRAS mutations [37, 38]. Moreover,
BRAF mutations have been reported to be characteristic
of the peculiar subtype of pancreas cancer named “me-
dullary” [38, 39], but none of our cases corresponded to
such subtype.
Correlation of expression, methylation and copy number
status of RASSF1
RASSF1 alteration has been suggested as a molecular hall-
mark of pancreatic cancer [2]. In the attempt to clarify the
involvement of RASSF1 in this setting, we performed a
comprehensive analysis of expression, methylation and
Fig. 3 Methylation status of CpG Islands A and C in PDAC xenografts and cell lines. Panel a shows the mehylation level of 51 CpGs analyzed by
pyrosequencing in 14 PDAC xenografts and eight PDAC cell lines. On the left numbers refer to xenografts and cell lines as listed in Additional file 1:
Tables S1 and S2. Each of the 51 CpGs, 17 in the promoter and 34 in the first exon, is represented by a square. Numbers on top show the location of
CpG dinucleotides and transcription start site is indicated (+1). Any CpG is represented by a square that has one of four grey levels according to the
proportion of methylation detected, namely white, light grey, grey and black indicating a level of methylation of 0–20 %, 20–40 %, 40–60 % and >60 %,
respectively. Panel b reports the methylation status of the 51 CpGs in the eight indicated PDAC cell lines. Panels c and d report the methylation status of
the 37 CpGs whithin the CpG island C in the indicated PDAC xenografts and cell lines, respectively
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copy number status of this putative tumor suppressor
gene in a relatively large series of primary PDAC, xeno-
grafts and PDAC cell lines.
Rassf1a expression was downregulated in about
50 % of samples. However, such downregulation was
not correlated with the RASSF1 methylation status,
which indicates that RASSF1 methylation is not an es-
sential mechanism for regulating protein expression
in PDAC. This is the first study investigating RASSF1
isoforms expression in PDAC. RASSF1A, RASSF1B
and RASSF1C mRNAs were expressed in all xeno-
grafts and cell lines, and, as observed for immunohis-
tochemical data, no correlation between the expression
level of the RASSF1 isoforms and methylation of CpG
islands was found. However, RASSF1F was preferentially
expressed by cell lines lacking methylation at CpG island
A (Wilcoxon test, p = 0.008), in line with the results of
Dammann et al. [2, 3]. This suggests that methylation of
CpG island A may affect expression and splicing of
RASSF1 transcripts regulated by the same promoter. The
lack of correlation between the level of methylation of
CpG island A and RASSF1A mRNA level in PDAC xeno-
grafts and cell lines further suggests that methylation is
not decisive for transcription regulation of RASSF1 iso-
forms. No correlation was found between methylation
and outcome of disease, at variance with other cancer
types [13, 16–21]. A consistent number (71/96, 74 %)
of RASSF1 locus alterations was found in our series,
including 54 % (50/96) of losses and 22 % (21/96) of
gains. The frequency of RASSF1 loss found is similar
to that reported in a previous LOH microsatellite
study investigating 82 PDAC xenografts [26]. Notably,
among the 50 samples with loss of RASSF1 locus, 30
(60 %) had a normal chromosome 3 ploidy, while the
remaining 20 (40 %) samples had chromosome 3
polysomy. Previous studies documented frequent chromo-
somal 3 alterations in pancreatic cancer [25–27, 35, 36], in-
cluding in particular the allelic loss at 3p21.3 [24, 25].
Harada et al. observed frequent gains of chromosome 3 by
high-density single nucleotide polymorphism array (78 % of
cases), associated with losses in the specific region of
chromosome 3p21 [26], this might reflect a propensity for
3p21.3 loss to occur as a secondary event of large 3p dele-
tions, which involves regions coding for other tumor sup-
pressor genes. Interestingly, chromosome 3 poliploidy was
associated with a worse prognosis in our series, independ-
ently of the status of RASSF1 locus, while patients with a
disomic status of both CEP3 and RASSF1 had a similar
prognosis compared to patients with disomic CEP3 and
loss of RASSF1. It has been described that RASSF1 methy-
lation can have different roles depending on the ploidy sta-
tus and patient’s age in neuroblastoma [40]. However, there
is no correlation between methylation and ploidy status in
our PDAC series. It is possible that other tumor suppressor
genes in chromosome 3p may be implicated in the clinical
course of these tumors.
Conclusions
RASSF1 alterations occurring in PDAC mainly consist in
variations of expression of the different isoforms. Differ-
ent genetic mechanisms seem to contribute to RASSF1
deregulation in this setting, but RASSF1 methylation
does not seem to substantially affect RASSF1 isoforms
expression.
Additional files
Additional file 1: Table S1. Distribution of Rassf1a
immunohistochemical (IHC) expression, RASSF1 and CEP3 status analyzed
by fluorescence in situ hybridization analysis, and RASSF1A methylation-
specific PCR (MSP) analysis in 96 PDAC cases. Table S2. RASSF1A methylation
status (DNA pyrosequencing) and Rassf1a immunohistochemical (IHC)
expression in 14 xenografted PDAC tissues. Average methylation values of 51
CpGs in CpG island A of RASSF1A, of which 17 CpGs in the promoter and 34
CpGs in the first exon are shown. (PDX = PDAC xenografts). Table S3.
RASSF1A methylation status (DNA pyrosequencing) and Rassf1a
immunohistochemical (IHC) expression in eight PDAC-derived cell lines. Aver-
age methylation values of 51 CpGs in CpG island A of RASSF1A, of which 17
CpGs in the promoter and 34 CpGs in the first exon are shown. (DOCX 42 kb)
Additional file 2: Figure S1. Survival rate of PDAC patients with RASSF1
disomy, loss of 3p, loss of 3p with polysomic CEP3 (CEP3+) and excess of
CEP3 copy number. Figure S2. Expression of RASSF1A, RASSF1B and RASSF1C
by quantitative RT-PCR (qRT-PCR) in PDAC xenografts. The expression levels of
RASSF1A (A), RASSF1B (B) and RASSF1C (C) in 14 PDAC xenografts are shown.
Expression data are the mean of three measures obtained by quantitative real
time RT-PCR. Data were normalized using the expression level of the RPLPO
gene as an internal reference. Data were analyzed according to the comparative
method and standard (=1) was represented by the average expression of all
samples. Numbers under bars refer to PDAC xenografts (PDX) as listed in
Additional file 1: Table S2. Figure S3. Expression of RASSF1A, RASSF1B and
RASSF1C by quantitative RT-PCR (qRT-PCR) in eight PDAC cell lines. Expression
data are the mean of three measures obtained by quantitative real time RT-
PCR. Data were normalized using the expression level of the RPLPO gene as an
internal reference. Data were analyzed according to the comparative method
and standard (=1) was represented by the average expression of all sample.
Expression levels (mean+ SD) are represented by white bars. (DOC 301 kb)
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